Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.
Status:
NOT_YET_RECRUITING
Trial end date:
2032-10-01
Target enrollment:
Participant gender:
Summary
The primary objectives are to determine the recommended Phase 2 dose (RP2D) and optimal treatment regimen, characterize safety and tolerability, and evaluate preliminary efficacy of RYZ401 in subjects with NETs and other selected solid tumors expressing SSTRs.